{"id":390319,"date":"2019-12-04T00:00:00","date_gmt":"2019-12-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2019-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-03-31T10:46:02","modified_gmt":"2026-03-31T10:46:02","slug":"dlsfcg0006-2019-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0006-2019-biopharma-schizophrenia-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Schizophrenia | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies\u00a0including the continued genericization of key oral therapies, the availability of newer oral atypical antipsychotics (e.g., Otsuka \/ Lundbeck\u2019s Rexulti and Allergan \/ Gedeon Richter \/ Recordati\u2019s Vraylar \/ Reagila), and the intensifying competition among long-acting injectables (<abbr title=\"long-acting injectable\">LAI<\/abbr>s). Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for late-phase and recently approved therapies\u2014including new oral atypical antipsychotics (e.g., Alkermes\u2019s ALKS 3831), new\u00a0<abbr title=\"long-acting injectable\">LAI<\/abbr>s (e.g., Indivior\u2019s Perseris, Janssen\u2019s paliperidone six-month depot, Teva\u2019s TV-46000), and others (e.g., Intra-Cellular Therapies\u2019 lumateperone, Minerva Neurosciences\u2019\u00a0roluperidone, and Sunovion \/ Sumitomo Dainippon Pharma\u2019s SEP-363856). Meanwhile, the potential of early- to mid-phase therapies for negative symptoms and cognitive impairment associated with schizophrenia, which are symptoms on which drug developers are increasingly focusing, remains to be seen.<\/p>\n<p><strong>Questions\u00a0<\/strong><strong>Answered<\/strong><\/p>\n<ul>\n<li>What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?<\/li>\n<li>What factors drive and constrain the use of\u00a0<abbr title=\"long-acting injectable\">LAI<\/abbr>s of atypical antipsychotics? How is competition heating up in this segment?<\/li>\n<li>What are the biggest areas of unmet need? What is the line-up of late-phase emerging therapies with the potential to fulfill these needs?<\/li>\n<li>What would key late-phase emerging therapies need to demonstrate to compete effectively in this crowded market?<\/li>\n<\/ul>\n<p><strong>Product Description:\u00a0<\/strong>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Geographies:<\/strong>\u00a0United States,\u00a0<abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>35 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.<\/p>\n<p><strong>Forecast:<\/strong>\u00a0Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2028, segmented by brands \/ generics.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase III \/\u00a0<abbr title=\"preregistered\">PR<\/abbr>: 8 drugs. Coverage of select Phase II and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390319","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-schizophrenia","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390319\/revisions"}],"predecessor-version":[{"id":576573,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390319\/revisions\/576573"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}